New psychoactive substance use among regular psychostimulant users in Australia, 2010-2015 by Sutherland, R. et al.
1 
 
New Psychoactive Substance Use among Regular Psychostimulant Users in Australia, 2010-2015 
 
 Rachel Sutherland*1, Amy Peacock2, Elizabeth Whittaker1, Amanda Roxburgh1, Simon 
Lenton3, Allison Matthews2, Kerryn Butler1, Marina Nelson3, Lucinda Burns1, Raimondo Bruno2 
 
1National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, 2052, 
Australia 
2 School of Medicine (Psychology), Faculty of Health, University of Tasmania, Hobart, TAS, 7001, 
Australia 
 








Journal: Drug and Alcohol Dependence 
Number of manuscript pages: 11 
Number of tables: 9 
Number of figures: 0 
 
 
Corresponding Author*: Rachel Sutherland 
National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, 2052, 
AUSTRALIA; Phone: +61 2 9385 0256; Facsimile: +61 (0)2 9385 0222; E-mail: rachels@unsw.edu.au 
  
*Manuscript




Objective: To examine the rates and patterns of new psychoactive substance (NPS) use amongst 
regular psychostimulant users (RPU) in Australia. 
Method: Data were obtained from the 2010-2015 Ecstasy and related Drugs Reporting System 
(EDRS), which comprised a total cross-sectional sample of 4,122 RPU.  
Results: Recent use of ‘any’ NPS increased from 33% in 2010 to 40% in 2015, although trends of use 
differed significantly across NPS classes. The correlates associated with NPS use also varied across 
NPS classes: frequent (i.e. weekly or more) ecstasy users were more likely to report recent 
phenethylamine use; LSD users were more likely to report recent phenethylamine and tryptamine 
use; and daily cannabis users were more likely to report recent synthetic cannabinoid use than RPU 
who had not used NPS. ‘Poly’ NPS consumers were found to be a particularly high risk group and 
were significantly more likely to be younger, male, report daily cannabis use, report weekly or more 
ecstasy use, report recent LSD use, have higher levels of poly drug use, have overdosed on any drug 
in the past year, and to have engaged in past month criminal activity.  
Conclusion: NPS use has been established as a significant and ongoing practice amongst our sample 
of RPU. It appears that RPU seek out NPS with similar properties to the illicit drugs that they are 
already consuming, with poly NPS consumers found to be a particularly high risk group. 
Keywords: New psychoactive substances; NPS; synthetic cannabinoids; synthetic cathinones; 





Over the past decade, countries worldwide have witnessed the rapid emergence of substances 
collectively referred to as ‘new psychoactive substances’ (NPS). NPS are substances which often do 
not fall under international drug controls but which may pose a public health threat (United Nations 
Office on Drugs and Crime (UNODC), 2013). The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) has identified 13 categories of NPS: aminoindanes, arylalkylamines, 
arylcyclohexylamines, benzodiazepines, synthetic cannabinoids, synthetic cathinones, 
indolalkylamines (i.e. tryptamines), opioids, phenethylamines, piperazine derivates, piperidines and 
pyrrolidines, plants and extracts, and others (EMCDDA, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 
2013, 2014, 2015). In 2014, over 450 NPS were being monitored by EMCDDA, the majority of which 
fell into the synthetic cathinone and synthetic cannabinoid categories (EMCDDA, 2015).  
The extent to which NPS are used globally remains unclear, with prevalence rates varying 
considerably across countries. Data from the European Union indicated that, in 2014, 3% of people 
aged 15-24 had used an NPS in the past year, with use highest in Ireland, Spain and France (5% 
respectively) (European Commission, 2014). The Crime Survey for England and Wales found that 
0.6% and 0.5% of 16-59 year olds reported past year use of mephedrone and salvia respectively 
(Home Office, 2014); in the United States, 4.8% of adolescents (grade 8-12) reported past year use of 
synthetic cannabinoids in 2014 and 0.8% reported use of synthetic stimulants (Miech et al., 2014). In 
Australia, the 2013 National Drug Strategy Household Survey showed that 1.2% of the general 
population had used synthetic cannabinoids in the last 12 months, and 0.4% had used another NPS 
(Australian Institute of Health & Welfare (AIHW), 2014). 
Whilst general population estimates appear to be relatively low, rates of NPS use are elevated 
amongst high risk groups, such as illicit drug users and those engaged in the night time economy 
(Bretteville-Jensen et al., 2013; Bonar et al., 2014; Burns et al., 2014; Kelly et al., 2013; Moore et al., 
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2013; Stafford & Burns, 2015; Vento et al., 2014; Winstock, 2015). For example, a study of gay dance 
club patrons in London found that amongst those who had used ecstasy pills in the past month, 75% 
had also used mephedrone (Moore et al., 2013); whilst a survey of 1,740 nightlife venue patrons in 
the US found that 8.2% had used synthetic cannabinoids and 1.1% had used mephedrone in the past 
year (Kelly et al., 2013).  
Presently, there is limited literature on the socio-demographic profile of NPS consumers. Studies 
examining the correlates of NPS use have found that those who are younger, male, had used other 
drugs and had higher levels of poly drug use were more likely to have used an NPS (Bonar et al., 
2014; Bruno et al., 2012; Burns et al., 2014; Emmanuel & Attarad, 2006; Lawn et al., 2014; Palamar, 
2015; Palamar & Acosta, 2015). More detailed studies have also identified younger age of drug 
initiation, more problematic drug use (e.g. bingeing) and online purchasing behaviours as being 
correlated with NPS use (Burns et al., 2014). Given the vast array of NPS that are available, it is likely 
that NPS consumers are a heterogeneous group. For example, in a recent study, stimulant NPS users 
were found to be similar to regular ecstasy users, while psychedelic NPS users were a distinct group 
of users who had initiated ecstasy use at a younger age, had higher levels of poly drug use and were 
more likely to experience legal, psychological and social drug-related problems (Bruno et al., 2012). 
Given these differences, it was argued that harm reduction messages need to be tailored according 
to the NPS being used.  
The public health risks associated with NPS are many and varied. Synthetic cannabinoids, for 
example, have been associated with acute and persistent psychosis, tachycardia, agitation, 
hallucinations, hypertension, vomiting, chest pain, seizures and myoclonia (Every-Palmer, 2010; 
Hermanns-Clausen, 2012); whilst mephedrone has been shown to impair working memory (Freeman 
et al., 2012), and has been associated with jaw clenching, reduced appetite, insomnia, agitation, 
tachycardia and dependence (Dargan et al., 2010; Dargan et al., 2011; Winstock et al., 2011). In 
addition, data from the Global Drug Survey showed that the risk of seeking emergency medical 
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treatment was 30 times higher amongst synthetic cannabinoid users than herbal cannabis users, 
whilst ‘other’ NPS users were about three times more likely to seek emergency medical treatment 
compared to traditional illicit drug users (Winstock, 2015).  
Given the different risk profiles associated with NPS use, it is essential to obtain a more nuanced 
understanding of who are most at risk for using these substances. This will improve our ability to 
tailor harm reduction messages to the appropriate target groups. Subsequently, the aims of this 
paper are twofold: 
1) To examine the prevalence of NPS use amongst a sample of regular psychostimulant users (RPU) 
in Australia, from 2010-2015.  
2) To determine whether correlates of use vary across the following five NPS classes; 
phenethylamines, tryptamines, synthetic cannabinoids, synthetic cathinones, and ‘poly’ NPS (i.e. use 
of more than one NPS class). 
2. Method 
2.1 Study design  
This paper uses six years of data (2010-2015) from the Ecstasy and related Drugs Reporting System 
(EDRS) (for full protocol details, see Sindicich & Burns, 2015). The EDRS is a national monitoring 
study aimed at detecting emerging trends in illicit drug markets and has been conducted annually in 
all Australian jurisdictions since 2003. The EDRS has received ethical approval from the University of 
New South Wales Human Research Ethics Committee (HC10071, HC15015), as well as from the 
relevant ethics committees in each jurisdiction.  
2.2 Participants and procedure 
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EDRS participants (hereafter referred to as ‘regular psychostimulant users’ (RPU)) comprised a non-
random self-selected sample recruited annually through street-press advertisements, online forums 
and peer referral. Eligibility criteria were; at least monthly use of ecstasy or psychostimulants in the 
preceding six months, 16 years of age or older, and residence in the city of interview for at least 12 
months prior to the interview. Face-to-face one-hour structured interviews were conducted by 
trained interviewers at a negotiated time and location. All information was confidential and 
anonymous.  
2.2 Measures relevant to the current study 
2.2.1 Outcome variables 
From 2010-2015, participants were asked about their past six month use of 26 specific NPS (see 
Table 1 for a full list, with street names provided in brackets); an open text ‘other’ option was 
provided to capture any additional NPS not listed in the survey. These NPS have been categorised 
into eight of the thirteen categories identified by the EMCDDA; namely synthetic cannabinoids, 
synthetic cathinones (i.e. stimulant and entactogen phenethylamines), phenethylamines (i.e. 
psychedelic phenethylamines), tryptamines, piperazines, plant and extracts, aminoindanes and 
arylcyclohexylamines. 
2.2.2 Correlates 
In addition to demographic questions (i.e. age, sex, sexual orientation, employment and educational 
status), participants were asked about their past six-month use of licit and illicit substances; the total 
number of illicit drug classes used in the past six months (excluding NPS) was used to measure levels 
of poly drug use (maximum of 17 drug classes). Participants completed the 5-item Severity of 
Dependence Scale (SDS; Gossop et al., 1995) in relation to ecstasy use, whereby a cut-off score of ≥3 
was considered indicative of ecstasy dependence (Bruno et al., 2011). Participants were also asked if 
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they had binged on stimulants in the past six months (defined as the use of stimulants for 48 hours 
or more without sleep). 
The Alcohol Use Disorders Identification Test (AUDIT) was administered to identify participants with 
potential alcohol-related problems (Saunders et al., 1993). A cut-off score of ≥16 was used to 
measure hazardous and harmful alcohol use (Babor & Higgins-Biddle, 2000). From its inception, the 
EDRS has measured crime using the Criminality Scale of the Opiate Treatment Index (OTI; Darke et 
al., 1991). This scale gathers self-report data on four types of crime: property crime; dealing; fraud; 
and violent crime (in the month preceding interview).  
Across all years, participants were administered the Kessler 10 (K10) Psychological Distress Scale to 
assess psychological distress (Kessler et al., 2003). The K10 is a 10-item screening tool utilizing a five-
point response scale (1 ‘none of the time’ to 5 ‘all of the time’); a cut-off score of ≥22 (score range 
10-50) was used to measure high to very high psychological distress (Andrews & Slade, 2001). 
Participants also answered self-report questions about their mental health over the previous six-
month period. 
Participants were asked if they had participated in the EDRS previously; this question was used to 
exclude repeat participants.  
2.3 Statistical analysis 
2.3.1 Rates of NPS use 
Rates of use were generated by collapsing the various NPS to determine if participants had 
consumed ‘any’ NPS in the six months preceding interview. Using the groupings identified by the 
EMCDDA, rates of use were then broken down into the following classes; synthetic cannabinoids, 
synthetic cathinones, phenethylamines, tryptamines, piperazines, plants and extracts, aminoindanes 
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and arylcyclohexylamines. Paired comparisons of percentages reporting use were made across 
adjacent years (e.g. 2010-2011; 2011-2012) with 95% confidence intervals (95% CI) reported.  
2.3.2 Correlates of NPS use 
Socio-demographic profiles were compared across the four most commonly used NPS classes (i.e. 
synthetic cathinones, synthetic cannabinoids, phenethylamines and tryptamines). The sample was 
divided into groups based on use of these substances in the six months preceding interview and 
compared to non NPS using participants (e.g. recent cathinone use only vs. no recent NPS use). In 
order to maintain distinct groups of NPS users (see Supplementary Material, Table 8 for overlap 
between NPS classes), participants who had used more than one NPS class were excluded from this 
analysis and included in the ‘poly’ NPS use group. As synthetic cannabinoids were first specifically 
asked about in 2011, this analysis was limited to 2011-2015 data (with all repeat participants 
excluded from 2012-2015 data).  
Between-group comparisons of categorical variables were analysed using odds ratios (OR) with 95% 
confidence intervals reported. For normally distributed continuous variables, t-tests were employed 
with means and standard deviations (SDs) reported. The Benjamini-Hochberg procedure was applied 
to control the false discovery rate and was used because it yields much greater power than the 
widely applied Bonferroni technique (Thissen et al., 2002).  
Variables found to be significant based on bivariate comparisons were entered into a multivariable 
logistic regression model, which estimated adjusted odds ratios (AOR) after controlling for potential 
confounders. To allow comparability across the five NPS categories, the same variables were entered 
into each of the regression models (this allows us to determine if the same variables are associated 
with different NPS classes and if they differ in magnitude). Associations were set for statistical 
significance at p < 0.05. All analyses were conducted using IBM SPSS Statistics for Windows release 




3.1 Demographics  
Across 2010-2015, 4,122 participants were recruited and interviewed for the EDRS, of which 529 
were repeat participants (see Supplementary Material, Table 7). Sixty-four percent of the entire RPU 
cohort were male with a mean age of 23.6 years (SD 6.2; range 16-64), 97% were of English speaking 
background, 47% were tertiary qualified, 69% were employed in some capacity, 32% were students, 
16% were unemployed and 3% were currently in drug treatment. Twelve percent of the 2010-2015 
cohort identified as gay, lesbian, bisexual or transgendered (GLBT). More detailed demographics of 
each year’s sample have been reported elsewhere (Sindicich & Burns, 2011, 2012, 2013, 2014, 
2015). 
3.2 Rates of recent NPS use  
From 2010-2015, 41.9% of the entire sample (n=1,655) reported use of ‘any’ NPS in the six months 
preceding interview. Specifically, one-third (32.9%) of RPU reported recent use of any NPS in 2010; 
this increased to 41.7% in 2011 (p=0.002), before reaching a peak of 51.6% in 2012 (p=0.002). Recent 
NPS use remained stable in 2013 (46.6%), before declining significantly in 2014 (40.6%; p=0.023) and 
then stabilising in 2015 (40.2%) (Table 1).  
Insert Table 1 
Looking at the different classes of NPS (see Table 1), cathinones were originally the most prevalent 
NPS being used by participants, with almost one-fifth (18.5%) of RPU reporting recent (i.e. past six 
month) use in 2010. However, by 2015 this had declined significantly, with 7.7% reporting use of 
cathinones in the six months preceding interview (p<0.001). Conversely, in 2010 both 
phenethylamines and tryptamines had been used by 8% of RPU in the six months preceding 
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interview; however, by 2015 rates of use had increased to 18.6% (p<0.001) and 10.9% (p=0.037) 
respectively, making them the two most commonly used groups of NPS in these years.  
The use of synthetic cannabinoids was specifically asked about for the first time in 2011, with 6.6% 
of RPU reporting use within the six months preceding interview. This increased significantly in 2012 
to 16.1% of the sample (p<0.001) and remained stable in 2013 (16.1%). However, in 2014 use of 
recent synthetic cannabinoids declined to rates observed in 2011 (6.9%; p<0.001), before stabilising 
in 2015 (6.4%).  
The use of piperazines, plant-based NPS and aminoindanes remained uncommon across all years. 
Specifically, from 2010-2015, the use of piperazines declined from 4.9% to 0% (p<0.001); plant-based 
NPS increased from 2.0% to 5.0% (p=0.005); and there was no change in the use of aminoindanes or 
arylcyclohexylamines.  
These trends remained consistent even when repeat participants were excluded (see Supplementary 
Material, Table 8).  
3.2 Correlates of NPS use  
3.2.1 Phenethylamines 
At the bivariate level, RPU who reported recent phenethylamine use were more likely to be under 
the age of 25 (OR 3.41, p<0.001), male (OR 1.67, p=0.001), report weekly or more ecstasy use (OR 
1.86, p<0.001), report recent (i.e., past six month) LSD use (OR 3.06, p<0.001), and report recent use 
of a greater number of drug classes (p<0.001), when compared to RPU who had not used any NPS in 
the preceding six months.     
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When significant bivariate correlates were entered into a multivariable logistic regression model 
(controlling for year), age, sex, weekly or more ecstasy use, recent LSD use and greater levels of poly 
drug use remained significant.  
Insert Table 2 
3.2.2 Tryptamines 
At the bivariate level, RPU who reported recent tryptamine use were more likely to report being 
male (OR 1.72, p=0.008), weekly or more ecstasy use (OR 1.89, p<0.001), recent LSD use (OR 4.14, 
p<0.001), daily cannabis use (OR 2.89, p<0.001), having binged on a stimulant drug (OR 1.71, 
p=0.004), use of a greater number of drug classes (5.9 vs. 4.3, p<0.001), and past month criminal 
activity (OR 2.11, p<0.001), when compared to RPU who had not used any NPS in the preceding six 
months. 
When the variables significant at the bivariate level were entered into a multivariable logistic 
regression model, controlling for year, the following variables remained significant; daily cannabis 
use, recent LSD use and greater levels of poly drug use.  
Insert Table 3 
3.2.3 Synthetic cannabinoids 
At the bivariate level, RPU who reported recent use of synthetic cannabinoids were more likely to 
report daily tobacco use (OR 1.76, p=0.001), daily cannabis use (OR 2.74, p<0.001), and past month 
criminal activity (OR 2.10, p<0.001), when compared to RPU who had not used any NPS in the 
preceding six months. Conversely, recent cocaine users were less likely to report recent use of 
synthetic cannabinoids (OR 0.46, p=0.001). 
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When the variables significant at the bivariate level were entered into a multivariable logistic 
regression model, controlling for year, the following variables were significant; daily cannabis use, 
recent cocaine use, past month criminal activity and greater levels of poly drug use.   
Insert Table 4 
3.2.4 Synthetic cathinones 
No variables were significantly correlated with recent synthetic cathinone use at the bivariate level. 
When a multivariable logistic regression was conducted (controlling for year), daily tobacco use and 
greater levels of poly drug use were found to be significantly associated with recent synthetic 
cathinone use.  Cocaine use was also associated with recent synthetic cathinone use, although this 
did not reach statistical significance.   
Insert Table 5 
3.2.5 Poly NPS use 
At the bivariate level, RPU who reported poly-NPS use in the past six months were more likely to be 
under the age of 25 (OR 1.77, p<0.001), male (OR 2.23, p<0.001), have initiated ecstasy use before 18 
years of age (OR 2.08, p<0.001), be unemployed (OR 1.48, p=0.005), report daily tobacco (OR 1.84, 
p<0.001) and cannabis (OR 2.89, p<0.001) use, report weekly or more ecstasy use (OR 2.34, p<0.001), 
report recent methamphetamine (OR 2.20, p<0.001) and LSD (OR 6.36, p<0.001) use, have binged on 
a stimulant drug (OR 2.56, p<0.001), have used a greater number of drug classes (p<0.001), have 
overdosed on a drug in the past year (OR 1.85, p<0.001), have engaged in past month criminal 
activity (OR 2.68, p<0.001), have high levels of psychological distress (OR 1.45, p=0.002), and to self-
report a mental health problem (OR 1.36, p=0.008), when compared to RPU who had not used any 
NPS in the preceding six months.  
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When the variables significant at the bivariate level were entered into a multivariable logistic 
regression model, controlling for year, the following variables remained significant; age, sex, daily 
cannabis use, weekly or more ecstasy use, recent LSD use, recent cocaine use, greater levels of poly 
drug use, past year drug overdose and past month criminal activity.  
Insert Table 6 
4. Discussion 
Despite fluctuations in use of specific forms over the past six years, the use of NPS has been 
established as a significant and ongoing practice amongst cross-sectional samples of RPU in 
Australia. Whilst it is difficult to make any direct comparisons to other studies (particularly given 
differences in time frames, samples and categorisations of NPS), it does appear that the changes 
noted in our sample mirror a number of international trends (European Commission, 2014; Home 
Office, 2014; Miech et al., 2014). Indeed, the globalisation of drug marketplaces has increased the 
accessibility and volatility of drugs such as NPS (Griffiths et al., 2010), and it is essential that projects 
such as the EDRS continue to monitor these substances so that changing trends can be detected in a 
timely manner.  
It is unknown what might be driving the specific trends observed in this paper; however, consumer 
acceptability and legislative changes are factors to consider. In 2013, EDRS participants were asked 
to rate the positive, negative and hangover effects of NPS, and how likely they would be to consume 
the substance again. DMT and 2CB received the highest ratings for pleasurability and likelihood to 
take again, whilst mephedrone and synthetic cannabinoids were viewed less favourably and 
reportedly had worse side effects (Matthews et al., 2013; Sindicich & Burns, 2014). Similarly, a self-
selecting online sample of DMT and NBOMe users found that when compared to other 
hallucinogens (i.e. LSD, magic mushrooms and ketamine) both DMT and NBOMe were rated 
favourably in terms of strength of effect and pleasurability (Lawn et al., 2014; Winstock et al., 2013). 
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In contrast, a global study of dual ‘natural’ and synthetic cannabis users found that 93% of 
participants preferred natural cannabis over synthetic cannabis (Winstock & Barratt, 2013). It seems 
likely that our sample of RPU experimented with a range of NPS, continuing to use those deemed 
‘acceptable’ in terms of their psychopharmacological and side effects, and ceasing use of those that 
were not. This theory is supported by findings that DMT, 2C-x and NBOMe remain the most 
commonly sold NPS on dark net marketplaces (Van Buskirk et al., 2015), however, it would be of 
benefit for future research to explicitly test this hypothesis through a close examination of the 
motivations for consuming specific NPS.   
 
Another factor to consider is the impact of legislative changes. Given the varying legislative 
frameworks across jurisdictions and the different dates of implementation, it is beyond the scope of 
this paper to determine whether the scheduling of NPS may have contributed to the trends 
observed in this paper. For example, in 2012, the Australian Therapeutic Goods Administration 
introduced a blanket ban on any type of synthetic cannabinoid that produced the same 
pharmacological effect as cannabis (Bright et al., 2013). In 2014 there was a significant decline in the 
use of synthetic cannabinoids amongst our sample of RPU; however, it is unclear if this was a lagged 
effect of the legislation (due to practices such as stockpiling) or if it was due to other, unrelated 
factors such as consumer acceptability. Given that this is a sample of illicit drug users, it seems 
unlikely that the criminalisation of NPS use would have dissuaded use of these substances, although 
it would have reduced their availability. Furthermore, legislative changes fail to explain the increase 
in phenethylamines and tryptamines observed in this paper. Nevertheless, it is important that 
further research evaluate the impact of Australian legislation on the NPS marketplace to provide an 
evidence-base for the efficacy of these regulatory approaches.  
 
This paper also illustrates the heterogeneity of NPS consumers, with the correlates of use varying 
across NPS classes. Perhaps not surprisingly, our findings suggest that RPU seek out NPS that have 
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similar properties to the ‘traditional’ illicit drugs that they are already using. More specifically, 
frequent ecstasy users were more likely to report recent use of phenethylamine-type NPS, LSD users 
were more likely to report recent use of phenethylamines (many of which have psychedelic 
properties) and tryptamines, and daily cannabis users were more likely to report recent use of 
synthetic cannabinoids. Cocaine users were more likely to report recent use of synthetic cathinones, 
although this did not reach statistical significance.   
 
Use of a larger number of ‘established’ illicit drugs emerged as the only consistent predictor of NPS 
use. This suggests that NPS users may represent a more innovative group of ‘psychonaut’ drug users, 
a term used to describe people who actively seek out new substances for the purposes of achieving 
altered states of consciousness (EMCCDA, 2004). It is important to note that for participants using a 
single NPS class this did not equate to a greater likelihood of drug-related harms. This was somewhat 
surprising, particularly given that clinical studies have shown that drugs such as NBOMe have been 
linked to a number of deaths and hospitalisations, despite its short history of human consumption 
(Wood et al., 2015). 
 
Rather, poly-NPS users were found to be the riskiest group of NPS consumers; in addition to having 
high levels of poly-drug use, this group were also more likely to have engaged in past month criminal 
activity and to have overdosed on any drug in the past year. These behaviours carry serious public 
health implications, particularly given the ever increasing number of NPS being identified, the 
limited knowledge of the short- and long-term effects of these drugs, and a lack of information on 
how they interact with other drugs. It is recommended that credible harm reduction messages be 
disseminated amongst these populations, with a particular focus on the potential risks of combining 
NPS and ‘traditional’ illicit drugs (for example, see Winstock et al., 2010).  
  
4.1 Limitations  
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This study has certain limitations. Firstly, the EDRS sample is not representative, which means that 
our findings are not generalizable to all RPU in Australia. Rather, it is a sentinel sample which allows 
for the early identification of trends in illicit drug markets, which is particularly important when 
monitoring marketplaces which are rapidly changing (as is the case of NPS). Secondly, our analysis is 
reliant upon self-report data from participants which may be subject to bias. Although evidence 
points to sufficient validity and reliability of self-report in studies assessing illicit drug use (Darke, 
1998), it is possible that participants may have incorrectly identified the NPS being consumed (i.e. it 
may have been sold to them as one thing, but have been something else) and it would be of benefit 
for future studies to corroborate their findings through chemical analysis. Finally, the EDRS only 
specifically asked about 26 different NPS and as such rates of use may be underestimated.  
4.2 Conclusions 
Whilst NPS use has been established as a significant and ongoing practice amongst our sample of 
RPU, it remains a highly dynamic marketplace with the popularity of NPS classes changing 
significantly across 2010-2015. It appears that RPU seek out NPS with similar properties to the 
traditional illicit drugs that they are already consuming. Poly NPS consumers were found to be a 
particularly high risk group and as such it is essential that credible harm reductions messages be 
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Table 1: Rates# of NPS amongst RPU, 2010-2015  
 2010 % 2011 % 
 (95% CI; p) 
2012 % 
 (95% CI; p) 
2013 %  
(95% CI; p) 
2014 %  
(95% CI; p) 
2015 %  
(95% CI; p) 
2010-2015* % 
95% CI; p value 
SYNTHETIC CATHINONES  
Mephedrone (miaow, 4MMC); Methylone (bk-


















  0.07, 0.14; 
p<0.001 
PHENETHYLAMINES  
2C-I; 2C-B (Bromo, TWOs, trystacy);    2C-E 
(hummingbird, europa); 2C-Other; Benzo Fury (6-








































SYNTHETIC CANNABINOIDS  
K2/Spice; Kronic; Other synthetic cannainoid 
 


































  0.03, 0.07; 
p<0.001 
PLANTS & EXTRACTS  
LSA (Hawaiian Baby); Mescaline; Salvia 














































-0.02, 0.01;  
p=0.369 





















#in the past six months; *for synthetic cannabinoids this refers to 2011-2015 figures; for aminoindanes and arylcyclohexylamines this refers to 2012-2015 figures; Pairwise comparisons were made across adjacent 
years; i.e. 2010 vs 2011; 2011 vs 2012; 2012 vs 2013; 2013 vs 2014; 2014 vs 2015; 95% CI refers to the differences across adjacent years, except for the final column where they refer to differences in 2010 vs 2015 
percentages;        = a significant increase in 2010 vs 2015 figures;         = a significant decrease in 2010 vs 2015 figures. − no change in 2010 vs 2015 figures. Significant findings have been bolded. 
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Table 2: Correlates of recent phenethylamine use amongst RPU, 2011-2015 
Note: OR = odds ratio; CI=confidence interval; AOR=adjusted odds ratio; SDS=severity of dependence scale; GLBT=gay, lesbian, bisexual or transgendered. 
*denotes significance using the Benjamini-Hochberg procedure; #in the six months preceding interview; ^Maximum of 17 drug classes (includes ecstasy, methamphetamine, illicit pharmaceutical stimulants, cocaine, 
LSD, MDA, ketamine, GHB, amyl nitrite, nitrous oxide, cannabis, heroin, other opioids, illicit antidepressants, illicit benzodiazepines, magic mushrooms, steroids). 
a Bivariate analysis were conducted, with odds ratios (OR) presented here for categorical outcomes; independent samples t-tests were conducted for parametric continuous data. 
b Multivariable analyses were conducted using significant variables from all five bivariate models:  i.e. significant variables from the phenethylamine bivariate comparisons (age, sex, weekly or more ecstasy use, LSD 
use, poly drug use and past month criminal activity), and significant variables from the tryptamine, synthetic cannabinoid and poly NPS bivariate comparisons ( age of ecstasy initiation, methamphetamine use, daily 
tobacco use, daily cannabis use, cocaine use, binged on a stimulant drug,  employment status, overdose, K10 score and mental health problem). Year was also included in the model to control for changes over time.    
                    Phenethylamine use past six months                                                        Multivariable 










 95% CI p-value 
Demographics                              Age (<25) % 69.2 88.4 3.41 (2.28, 5.08) <0.001* 2.66 1.71, 4.14 <0.001 
Sex (male) % 60.3 71.7 1.67 (1.25, 2.23) 0.001* 1.59 1.15, 2.21 0.005 
Age first tried ecstasy (<18) 46.4 54.4 1.38 (1.06, 1.80) 0.018 1.03 0.75, 1.40 0.874 
Tertiary qualifications % 47.9 39.9 0.72 (0.55, 0.95) 0.019    
GLBT % 11.0 9.6 0.85 (0.54, 1.33) 0.481    
Unemployed % 15.3 13.1 0.84 (0.57, 1.24) 0.373 0.86 0.54, 1.36 0.513 
Drug Use                        Daily tobacco use
# 
% 38.6 40.0 1.06 (0.81, 1.39) 0.673 1.02 0.73, 1.42 0.910 
Daily cannabis use
# 
% 13.5 16.5 1.27 (0.88, 1.82) 0.202 1.16 0.72, 1.72 0.623 
Ecstasy use
# (
≥weekly) % 23.0 35.7 1.86 (1.39, 2.47) <0.001* 1.69 1.21, 2.36 0.002 
Methamphetamine use
# 
% 44.8 41.0 0.86 (0.65, 1.12) 0.259 0.78 0.55, 1.09 0.146 
LSD use
# 
% 29.5 56.2 3.06 (2.34, 4.01) <0.001* 1.58 1.12, 2.23 0.009 
Cocaine use
# 
% 41.3 44.2 1.13 (0.86, 1.47) 0.379 0.71 0.51, 0.99 0.045 
AUDIT score ≥16 % 38.4 32.1 0.76 (0.57, 1.01) 0.055    
Binged on stimulant drug
#
 % 32.9 34.8 1.09 (0.83, 1.44) 0.543 0.98 0.70, 1.37 0.901 
Ecstasy SDS score (≥3)
#
 % 20.0 22.8 1.18 (0.83, 1.68) 0.347    
Number of drug classes
#^
 (mean; SD) 4.3 (1.97) 5.5 (2.11) t318=-8.67 <0.001* 1.29 1.18, 1.42 <0.001 
Overdose (past year) % 35.2 40.8 1.27 (0.97, 1.67) 0.084 1.18 0.87, 1.60 0.293 
Other                    Any crime (past month) % 30.4 42.5 1.69 (1.29, 2.22) <0.001* 1.24 0.90, 1.69 0.191 
K10 score ≥22 % 27.4 24.9 0.88 (0.65, 1.19) 0.401 0.70 0.47, 1.02 0.065 
Self-reported mental health problem
# 
% 28.7 31.9 1.16 (0.87, 1.55) 0.302 1.38 0.96, 1.96 0.079 
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Table 3: Correlates of recent tryptamine use amongst RPU, 2011-2015 
Note: OR = odds ratio; CI=confidence interval; AOR=adjusted odds ratio; SDS=severity of dependence scale; GLBT=gay, lesbian, bisexual or transgendered. 
 *denotes significance using the Benjamini-Hochberg procedure; #in the six months preceding interview; ^Maximum of 17 drug classes (includes ecstasy, methamphetamine, illicit pharmaceutical stimulants, cocaine, 
LSD, MDA, ketamine, GHB, amyl nitrite, nitrous oxide, cannabis, heroin, other opioids, illicit antidepressants, illicit benzodiazepines, magic mushrooms, steroids). 
a Bivariate analysis were conducted, with odds ratios (OR) presented here for categorical outcomes; independent samples t-tests were conducted for parametric continuous data. 
b Multivariable analyses were conducted using the significant variables from all five bivariate models; i.e. significant variables from the tryptamine bivariate comparisons (sex, daily cannabis use, weekly or more 
ecstasy use, LSD use, binged on a stimulant drug, poly drug use and past month criminal activity), and significant variables from the phenethylamine, synthetic cannabinoid and poly NPS bivariate comparisons (age, 
age of ecstasy initiation, methamphetamine use, daily tobacco use, cocaine use, employment status, overdose, K10 score and mental health problem). Year was also included in the model to control for changes over 
time.    
                      Tryptamine use past six months                                                                                    Multivariable 
 No NPS use 
(n=1,693) 






 95% CI p-value 
Demographics                              Age (<25) % 69.2 65.0 0.83 (0.56, 1.22) 0.335 0.80 0.51, 1.26 0.338 
Sex (male) % 60.3 72.4 1.72 (1.15, 2.59) 0.008* 1.53 0.97, 2.39 0.065 
Age first tried ecstasy (<18) 46.4 56.9 1.53 (1.06, 2.21) 0.024 1.10 0.73, 1.67 0.646 
Tertiary qualifications % 47.9 50.4 1.11 (0.77, 1.60) 0.591    
GLBT % 11.0 8.1 0.71 (0.37, 1.39) 0.315    
Unemployed % 15.3 19.5 1.34 (0.84, 2.14) 0.213 0.99 0.57, 1.72 0.976 
Drug Use                        Daily tobacco use
# 
% 38.6 45.5 1.33 (0.92, 1.92) 0.129 0.94 0.60, 1.47 0.790 
Daily cannabis use
# 
% 13.5 31.1 2.89 (1.92, 4.35) <0.001* 2.25 1.38, 3.67 0.001 
Ecstasy use
# (
≥weekly) % 23.0 36.1 1.89 (1.28, 2.78) 0.001* 1.24 0.79, 1.95 0.352 
Methamphetamine use
# 
% 44.8 50.4 1.25 (0.87, 1.80) 0.230 0.77 0.49, 1.21 0.255 
LSD use
# 
% 29.5 63.4 4.14 (2.83, 6.06) <0.001* 2.18 1.37, 3.46 0.001 
Cocaine use
# 
% 41.3 47.2 1.27 (0.88, 1.83) 0.203 0.82 0.53, 1.29 0.398 
AUDIT score ≥16 % 38.4 30.3 0.70 (0.47, 1.04) 0.074    
Binged on stimulant drug
# 
% 32.9 45.5 1.71 (1.18, 2.47) 0.004* 1.23 0.80, 1.91 0.348 
Ecstasy SDS score (≥3)
#
 % 20.0 11.5 0.52 (0.27, 0.98) 0.041    
Number of drug classes
#^
 (mean; SD) 4.3 (1.97) 5.9 (1.85) t1800=-8.74 <0.001* 1.31 1.16, 1.48 <0.001 
Overdose (past year) % 35.2 44.7 1.49 (1.03, 2.16) 0.033 1.34 0.89, 2.01 0.160 
Other                    Any crime (past month) % 30.4 48.0 2.11 (1.46, 3.05) <0.001* 1.51 0.99, 2.30 0.059 
K10 score ≥22 % 27.4 30.0 1.13 (0.76, 1.70) 0.544 0.73 0.44, 1.20 0.212 
Self-reported mental health problem
# 
% 28.7 35.2 1.35 (0.92, 1.99) 0.124 1.38 0.86, 2.20 0.183 
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Table 4: Correlates of recent synthetic cannabinoid use amongst RPU, 2011-2015 
Note: OR = odds ratio; CI=confidence interval; AOR=adjusted odds ratio; SDS=severity of dependence scale; GLBT=gay, lesbian, bisexual or transgendered. 
 *denotes significance using the Benjamini-Hochberg procedure; #in the six months preceding interview; ^Maximum of 17 drug classes (includes ecstasy, methamphetamine, illicit pharmaceutical stimulants, cocaine, 
LSD, MDA, ketamine, GHB, amyl nitrite, nitrous oxide, cannabis, heroin, other opioids, illicit antidepressants, illicit benzodiazepines, magic mushrooms, steroids). 
a Bivariate analysis were conducted, with odds ratios (OR) presented here for categorical outcomes; independent samples t-tests were conducted for parametric continuous data. 
b Multivariable analyses were conducted using significant variables from all five bivariate models: i.e. significant variables from the synthetic cannabinoid bivariate comparisons (daily tobacco use, daily cannabis use, 
cocaine use and past month criminal activity), and significant variables from the phenethylamine and tryptamine bivariate comparisons (age, sex, age of ecstasy initiation, weekly or more ecstasy use, LSD use, 
methamphetamine use, employment status, binged on a stimulant drug, overdose, poly drug use, K10 score and mental health problem). Year was also included in the model to control for changes over time.    
 Synthetic cannabinoid use past six months            Multivariable  
 No NPS use 
(n=1,693) 






 95% CI p-value 
Demographics                              Age (<25) % 69.2 75.2 1.35 (0.91, 2.00) 0.138 1.45 0.92, 2.27 0.108 
Sex (male) % 60.3 67.4 1.36 (0.94, 1.96) 0.098 1.37 0.93, 2.03 0.115 
Age first tried ecstasy (<18) 46.4 56.7 1.52 (1.07, 2.14) 0.018 1.19 0.81, 1.74 0.382 
Tertiary qualifications % 47.9 44.0 0.85 (0.60, 1.21) 0.371    
GLBT % 11.0 12.8 1.18 (0.70, 1.98) 0.533    
Unemployed % 15.3 17.7 1.19 (0.76, 1.88) 0.443 0.90 0.55, 1.49 0.682 
Drug Use                        Daily tobacco use
# 
% 38.6 52.5 1.76 (1.24, 2.48) 0.001* 1.30 0.87, 1.93 0.199 
Daily cannabis use
# 
% 13.5 30.0 2.74 (1.86, 4.04) <0.001* 2.13 1.37, 3.32 0.001 
Ecstasy use
# (
≥weekly) % 23.0 23.6 1.03 (0.69, 1.55) 0.878 0.76 0.49, 1.18 0.216 
Methamphetamine use
# 
% 44.8 53.2 1.40 (0.99, 1.97) 0.055 0.95 0.63, 1.43 0.813 
LSD use
# 
% 29.5 33.3 1.19 (0.83, 1.72) 0.340 0.80 0.52, 1.25 0.330 
Cocaine use
# 
% 41.3 28.4 0.56 (0.39, 0.82) 0.003* 0.46 0.30, 0.72 0.001 
AUDIT score ≥16 % 38.4 45.7 1.35 (0.95, 1.91) 0.090    
Binged on stimulant drug
#
 % 32.9 42.6 1.51 (1.07, 2.15) 0.019 1.19 0.80, 1.77 0.395 
Ecstasy SDS score (≥3)
#
 % 20.0 20.5 1.03 (0.66, 1.61) 0.898    
Number of drug classes
#^
 (mean; SD) 4.3 (1.97) 4.70 (1.93) t1820=-2.47 0.014 1.16 1.03, 1.30 0.015 
Overdose (past year) % 35.2 38.3 1.14 (0.80, 1.63) 0.456 1.16 0.76, 1.63 0.575 
Other                    Any crime (past month) % 30.4 47.9 2.10 (1.48, 2.98) <0.001* 1.50 1.02, 2.22 0.040 
K10 score ≥22 % 27.4 32.9 1.29 (0.90, 1.87) 0.169 0.88 0.56, 1.36 0.554 
Self-reported mental health problem
#
 % 28.7 36.9 1.45 (1.02, 2.08) 0.040 1.37 0.90, 2.09 0.139 
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 Table 5: Correlates of recent synthetic cathinone use amongst RPU, 2011-2015 
Note: OR = odds ratio; CI=confidence interval; AOR=adjusted odds ratio; SDS=severity of dependence scale; GLBT=gay, lesbian, bisexual or transgendered. 
 *denotes significance using the Benjamini-Hochberg procedure; #in the six months preceding interview; ^Maximum of 17 drug classes (includes ecstasy, methamphetamine, illicit pharmaceutical stimulants, cocaine, 
LSD, MDA, ketamine, GHB, amyl nitrite, nitrous oxide, cannabis, heroin, other opioids, illicit antidepressants, illicit benzodiazepines, magic mushrooms, steroids).  
a Bivariate analysis were conducted, with odds ratios (OR) presented here for categorical outcomes; independent samples t-tests were conducted for parametric continuous data. 
b Multivariable analyses were conducted using significant variables from all five bivariate models: i.e. significant variables from the phenethylamine, tryptamine, synthetic cannabinoid and poly NPS bivariate 
comparisons (age, sex, age of ecstasy initiation, weekly or more ecstasy use, LSD use, daily tobacco use, daily cannabis use, cocaine use, methamphetamine use, employment status, binged on a stimulant drug, 
overdose, poly drug use, past month criminal activity, K10 score and mental health problem). Year was also included in the model to control for changes over time.     
 Synthetic cathinone use past six months            Multivariable  
 No NPS use 
(n=1,693) 






 95% CI p-value 
Demographics                              Age (<25) % 69.2 64.9 0.82 (0.53, 1.27) 0.379 0.79 0.48, 1.30 0.352 
Sex (male) % 60.3 60.6 1.01 (0.66, 1.55) 0.949 1.10 0.69, 1.76 0.680 
Age first tried ecstasy (<18) 46.4 50.0 1.16 (0.76, 1.75) 0.495 1.00 0.63, 1.59 0.998 
Tertiary qualifications % 47.9 58.1 1.51 (0.99, 2.30) 0.056    
GLBT % 11.0 9.6 0.85 (0.42, 1.72) 0.657    
Unemployed % 15.3 9.6 0.59 (0.29, 1.18) 0.130 0.58 0.28, 1.22 0.152 
Drug Use                        Daily tobacco use
# 
% 38.6 46.7 1.40 (0.92, 2.13) 0.120 1.65 1.03, 2.66 0.038 
Daily cannabis use
# 
% 13.5 16.0 1.21 (0.69, 2.14) 0.505 0.91 0.46, 1.78 0.782 
Ecstasy use
# (
≥weekly) % 23.0 18.7 0.77 (0.45, 1.32) 0.338 0.71 0.40, 1.26 0.246 
Methamphetamine use
# 
% 44.8 51.1 1.28 (0.85, 1.95) 0.237 0.96 0.58, 1.58 0.858 
LSD use
# 
% 29.5 30.1 1.03 (0.65, 1.62) 0.902 0.78 0.44, 1.36 0.376 
Cocaine use
# 
% 41.3 53.2 1.62 (1.07, 2.45) 0.023 1.36 0.82, 2.24 0.230 
AUDIT score ≥16 % 38.4 42.6 1.19 (0.78, 1.81) 0.426    
Binged on a stimulant drug
#
 % 32.9 36.2 1.16 (0.75, 1.79) 0.441 1.02 0.62, 1.68 0.933 
Ecstasy SDS score (≥3)
#
 % 20.0 26.6 1.45 (0.87, 2.42) 0.157    
Number of drug classes
#^
 (mean; SD) 4.3 (1.97) 4.88 (1.78) t1771=-2.87 0.004 1.16 1.01, 1.34 0.037 
Overdose (past year) % 35.2 33.0 0.91 (0.58, 1.41) 0.664 0.82 0.51, 1.31 0.397 
Other                    Any crime (past month) % 30.4 38.3 1.42 (0.93, 2.18) 0.107 1.30 0.80, 2.12 0.287 
K10 score ≥22 % 27.4 29.0 1.08 (0.68, 1.72) 0.737 1.03 0.60, 1.76 0.927 
Self-reported mental health problem
#
 % 28.7 34.0 1.28 (0.83, 1.99) 0.266 1.23 0.74, 2.06 0.423 
28 
 
Table 6: Correlates of poly NPS use amongst RPU, 2011-2015 
Note: OR = odds ratio; CI=confidence interval; AOR=adjusted odds ratio; SDS=severity of dependence scale; GLBT=gay, lesbian, bisexual or transgendered. 
 *denotes significance using the Benjamini-Hochberg procedure; #in the six months preceding interview; ^Maximum of 17 drug classes (includes ecstasy, methamphetamine, illicit pharmaceutical stimulants, cocaine, 
LSD, MDA, ketamine, GHB, amyl nitrite, nitrous oxide, cannabis, heroin, other opioids, illicit antidepressants, illicit benzodiazepines, magic mushrooms, steroids). 
a Bivariate analysis were conducted, with odds ratios (OR) presented here for categorical outcomes; independent samples t-tests were conducted for parametric continuous data. 
b Multivariable analyses were conducted using significant variables from all five bivariate models: i.e. significant variables from the poly NPS bivariate comparisons (age, sex, age of ecstasy initiation, weekly or more 
ecstasy use, LSD use, daily tobacco use, daily cannabis use, methamphetamine use, employment status, binged on a stimulant drug, overdose, poly drug use, past month criminal activity, K10 score and mental 
health problem), and significant variables from the phenethylamine,  tryptamine  and synthetic cannabinoids bivariate comparisons (cocaine use). Year was also included in the model to control for changes over 
time.    
 Poly NPS use past six months            Multivariable  
 No NPS use 
(n=1,693) 






 95% CI p-value 
Demographics                              Age (<25) % 69.2 79.9 1.77 (1.36, 2.32) <0.001* 1.54 1.10, 2.16 0.011 
Sex (male) % 60.3 77.2 2.23 (1.73, 2.87) <0.001* 1.85 1.36, 2.52 <0.001 
Age first tried ecstasy (<18) 46.4 64.3 2.08 (1.66, 2.61) <0.001* 1.28 0.96, 1.71 0.095 
Tertiary qualifications % 47.9 43.1 0.83 (0.66, 1.03) 0.090    
GLBT % 11.0 11.1 1.00 (0.71, 1.42) 0.996    
Unemployed % 15.3 21.1 1.48 (1.12, 1.94) 0.005* 0.97 0.67, 1.39 0.858 
Drug Use                        Daily tobacco use
# 
% 38.6 53.7 1.84 (1.48, 2.30) <0.001* 1.15 0.86, 1.56 0.345 
Daily cannabis use
# 
% 13.5 31.2 2.89 (2.24, 3.73) <0.001* 1.67 1.19, 2.36 0.003 
Ecstasy use
# (
≥weekly) % 23.0 41.2 2.34 (1.86, 2.95) <0.001* 1.44 1.07, 1.95 0.017 
Methamphetamine use
# 
% 44.8 64.2 2.20 (1.76, 2.76) <0.001* 0.81 0.59, 1.10 0.180 
LSD use
# 
% 29.5 72.7 6.36 (4.98, 8.11) <0.001* 2.18 1.60, 2.97 <0.001 
Cocaine use
# 
% 41.3 44.6 1.15 (0.92, 1.43) 0.226 0.47 0.34, 0.65 <0.001 
AUDIT score ≥16 % 38.4 34.8 0.85 (0.68, 1.07) 0.173    
Binged on a stimulant drug
#
 % 32.9 55.6 2.56 (2.05, 3.20) <0.001* 1.28 0.95, 1.72 0.108 
Ecstasy SDS score (≥3)
#
 % 20.0 23.4 1.22 (0.93, 1.62) 0.158    
Number of drug classes
#^
 (mean; SD) 4.3 (1.97) 6.88 (2.40) t526=-19.99 <0.001* 1.56 1.44, 1.69 <0.001 
Overdose (past year) % 35.2 50.1 1.85 (1.49, 2.31) <0.001* 1.56 1.19, 2.06 0.001 
Other                    Any crime (past month) % 30.4 53.9 2.68 (2.14, 3.36) <0.001* 1.43 1.08, 1.90 0.013 
K10 score ≥22 % 27.4 35.5 1.45 (1.15, 1.84) 0.002* 0.83 0.60, 1.16 0.270 
Self-reported mental health problem
#




Table 7: Number of participants, 2010-2015 
 Total number of participants 
n 
Number of repeat participants  
n (%) 
2010 693 115 (16.6) 
2011 574 104 (18.1) 
2012 607 81 (13.3) 
2013 685 65 (9.5) 
2014 800 81 (10.1) 
2015 763 83 (10.9) 
 
Table 8: Recent NPS use: overlap between NPS classes, 2011-2015  




Piperazines Plants & 
extracts 
Aminoindanes 
Tryptamines (n) 140       
Synthetic cannabinoids (n) 86 69      
Synthetic cathinones (n) 89 77 33     
Piperazines (n) 5 5 5 10    
Plants & extracts (n) 56 69 44 29 3   
Aminoindanes (n) 7 5 4 3 1 4  
Arylcyclohexylamines (n) 18 23 7 16 0 1 2 




Table 9: Rates# of NPS use amongst RPU, 2010-2015 (excludes repeat participants) 
 2010 % 2011 % 
 (95% CI; p) 
2012 % 
 (95% CI; p) 
2013 %  
(95% CI; p) 
2014 %  
(95% CI; p) 
2015 %  
(95% CI; p) 
2010-2015* % 
95% CI; p value 
SYNTHETIC CATHINONES  
Mephedrone (miaow, 4MMC); Methylone (bk-MDMA); 

















 0.08,  0.15; 
p<0.001 
PHENETHYLAMINES  
2C-I; 2C-B (Bromo, TWOs, trystacy);    2C-E 
(hummingbird, europa); 2C-Other; Benzo Fury (6-APB); 





































-0.06,  -0.002; 
p=0.047 
SYNTHETIC CANNABINOIDS  
K2/Spice; Kronic; Other synthetic cannainoid 
 


































  0.03, 0.07; 
p<0.001 
PLANTS & EXTRACTS  
LSA (Hawaiian Baby); Mescaline; Salvia Divinorum; 
































-0.003,  0.02; 
p=0.325 
ARYLCYCLOHEXYLAMINES 
Methoxetamine (MXE)  










 -0.01, 0.01; 
p=0.902 





















Note: For synthetic cathinones, phenethylamines, tryptamines, piperazines, and plants & extracts, 2011-2015 figures exclude repeat participants. For synthetic cannabinoids, 2012-2015 figures exclude repeat 
participants. For aminoindanes and arylcyclohexylamines, 2013-2015 figures exclude repeat participants; #in the past six months; *for synthetic cannabinoids this refers to 2011-2015 figures; for aminoindanes and 
arylcyclohexylamines this refers to 2012-2015 figures. Pairwise comparisons made across adjacent years; i.e. 2010 vs 2011; 2011 vs 2012; 2012 vs 2013; 2013 vs 2014; 2014 vs 2015; 95% CI refers to the differences 
across adjacent years, except for the final column where they refer to differences in 2010 vs 2015 percentages.        = a significant increase in 2010 vs 2015 figures.       = a significant decrease in 2010 vs 2015 figures.  
− no change in 2010 vs 2015 figures. Significant findings have been bolded. 
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